Media headlines about Illumina (NASDAQ:ILMN) have been trending positive on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Illumina earned a media sentiment score of 2.67 on their scale. InfoTrie also gave media coverage about the life sciences company an news buzz score of 5 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Illumina’s ranking:
- Illumina, Inc. (ILMN) EVP Marc Stapley Sells 1,000 Shares (americanbankingnews.com)
- PÜR Launches Limited-Edition Makeup Collection In Support Of Universal Pictures’ And Illumination’s Dr. Seuss’ The Grinch (prweb.com)
- $1.35 EPS Expected for Illumina, Inc. (ILMN) This Quarter (americanbankingnews.com)
- Insider Selling: Illumina, Inc. (ILMN) SVP Sells 6,835 Shares of Stock (americanbankingnews.com)
- Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y (finance.yahoo.com)
Shares of NASDAQ:ILMN traded down $10.30 on Friday, reaching $329.25. The company’s stock had a trading volume of 1,192,300 shares, compared to its average volume of 931,320. Illumina has a 52-week low of $203.83 and a 52-week high of $372.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. The stock has a market capitalization of $47.44 billion, a price-to-earnings ratio of 82.31, a PEG ratio of 2.40 and a beta of 1.07.
Several equities analysts have issued reports on ILMN shares. Morgan Stanley upped their price objective on shares of Illumina from $195.00 to $210.00 and gave the company an “underweight” rating in a research note on Friday, July 13th. Piper Jaffray Companies upped their price objective on shares of Illumina from $272.00 to $329.00 and gave the company an “overweight” rating in a research note on Tuesday, July 17th. Canaccord Genuity restated a “buy” rating and issued a $340.00 price objective (up previously from $330.00) on shares of Illumina in a research note on Friday, July 27th. Barclays upped their price objective on shares of Illumina from $300.00 to $350.00 and gave the company an “overweight” rating in a research note on Tuesday, July 31st. Finally, Citigroup upped their price objective on shares of Illumina from $330.00 to $345.00 and gave the company a “buy” rating in a research note on Tuesday, July 31st. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $330.94.
In other news, SVP Oene Mark Van sold 1,091 shares of the company’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $354.18, for a total value of $386,410.38. Following the completion of the sale, the senior vice president now directly owns 11,126 shares of the company’s stock, valued at $3,940,606.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Marc Stapley sold 1,000 shares of the company’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $336.68, for a total transaction of $336,680.00. Following the completion of the sale, the executive vice president now directly owns 7,757 shares of the company’s stock, valued at $2,611,626.76. The disclosure for this sale can be found here. Insiders sold 53,464 shares of company stock valued at $17,883,331 over the last ninety days. Corporate insiders own 0.54% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Positive Press Coverage Somewhat Likely to Impact Illumina (ILMN) Share Price” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://sportsperspectives.com/2018/11/09/positive-press-coverage-somewhat-likely-to-impact-illumina-ilmn-share-price.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Read More: Leveraged Buyout (LBO)
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.